TENAX THERAPEUTICS, INC. — Form SCHEDULE 13D/A
Filed July 31, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 12/100
What the filing says
This is an amended Schedule 13D/A filing dated July 31, 2026, relating to beneficial ownership of Tenax Therapeutics, Inc. (market cap ~$23.8M). The filing was submitted by Christopher Thomas Giordano with a business address in Morrisville, NC. The document text itself is not provided in the filing extract, so no specific ownership percentages, share counts, dollar amounts, or substantive changes to beneficial ownership can be determined from the available text.
Why this rating
Amendment to 13D filing with no disclosed material facts or ownership data. Routine regulatory update; cannot assess business impact without actual filing content.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.